News
ONCT
1.140
+2.70%
0.030
Oncternal Therapeutics to Cut Most of Its Workforce
Dow Jones · 2d ago
Oncternal Therapeutics Announces Workforce Reduction and Executive Changes
TipRanks · 2d ago
ONCTERNAL THERAPEUTICS INC: EXPECTS $2.4 MILLION IN CHARGES FROM WORKFORCE REDUCTION
Reuters · 2d ago
Weekly Report: what happened at ONCT last week (1104-1108)?
Weekly Report · 6d ago
Oncternal Therapeutics Faces Workforce Reduction Challenges: Potential Risks and Implications
TipRanks · 11/08 06:01
Oncternal Therapeutics, Inc. Reports Financial Results for the Quarter Ended September 30, 2024
Press release · 11/06 23:24
Ionis Pharmaceuticals (IONS) Reports Q3 Loss, Tops Revenue Estimates
NASDAQ · 11/06 13:10
Weekly Report: what happened at ONCT last week (1028-1101)?
Weekly Report · 11/04 12:00
Oncternal Therapeutics Has Been Granted U.S. Patent Number 12,128,026 Titled "Selective Androgen Receptor Degrader Ligands And Methods Of Use Thereof (For The Treatment Of Prostate Cancer)"
Benzinga · 10/29 19:17
Weekly Report: what happened at ONCT last week (1021-1025)?
Weekly Report · 10/28 11:50
Biotech Alert: Searches spiking for these stocks today
TipRanks · 10/24 15:10
Oncternal Therapeutics announces updated data from Phase 1/2 study of ONCT-534
TipRanks · 10/22 13:05
ONCTERNAL THERAPEUTICS ANNOUNCES UPDATED SAFETY AND EFFICACY DATA FOR PHASE 1/2 STUDY OF ONCT-534 FOR THE TREATMENT OF R/R METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Reuters · 10/22 13:00
Weekly Report: what happened at ONCT last week (1014-1018)?
Weekly Report · 10/21 11:45
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Benzinga · 10/15 12:08
Weekly Report: what happened at ONCT last week (1007-1011)?
Weekly Report · 10/14 12:21
Weekly Report: what happened at ONCT last week (0930-1004)?
Weekly Report · 10/07 12:08
Weekly Report: what happened at ONCT last week (0923-0927)?
Weekly Report · 09/30 11:58
Weekly Report: what happened at ONCT last week (0916-0920)?
Weekly Report · 09/23 11:57
Weekly Report: what happened at ONCT last week (0909-0913)?
Weekly Report · 09/16 11:45
More
Webull provides a variety of real-time ONCT stock news. You can receive the latest news about Oncternal Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About ONCT
Oncternal Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of oncology therapies for the treatment of patients with cancers that have critical unmet medical needs. The Company’s product candidates include ONCT-534, ONCT-808, Zilovertamab, and ONCT-216. ONCT-534 is a dual-action androgen receptor inhibitor (DAARI), for the treatment of advanced castration-resistant prostate cancer (CRPC) and other androgen receptor (AR) driven diseases. ONCT-808 is an autologous chimeric antigen receptor (CAR-T) therapy that targets ROR1 for the treatment of hematologic malignancies and solid tumors. Zilovertamab is an investigational, humanized, monoclonal antibody designed to inhibit the function of Receptor tyrosine kinase-like Orphan Receptor 1 (ROR1). Zilovertamab has been evaluated in an investigator-initiated Phase 1b study of zilovertamab in combination with docetaxel in patients with mCRPC.